The short version of Thymosin fraction 5 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-23 and is reviewed periodically as new material appears.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
This is interpreted by some researchers to mean that although the incorporation of lactobacillic acid into the cell membrane has no significant influence on the physical properties of the membrane, it does change its chemical properties, which is an advantage for the organism. One example of a beneficial effect of lactobacillic acid is provided by Oenococcus oeni. The lactic acid bacterium is used in wine production to convert malic acid into lactic acid during malolactic fermentation into lactic acid, which in turn is converted into ethanol by baker's yeast. In this way, the acidity of the wine is reduced. In the process, Oenococcus oeni is exposed to relatively high concentrations of ethanol produced by yeasts during alcoholic fermentation. Studies of the cell membrane of the bacterium have shown that the biosynthesis rate of phospholidides is increased with increasing ethanol concentration in the surrounding culture medium. In addition, more lactobacillic acid is formed in the membrane lipids, while the content of cis vaccenic acid decreases. This is interpreted as a protective mechanism against the toxic effects of ethanol. The formation of lactobacillic acid helps the bacterium to adapt to unfavorable environmental conditions. A similar protective effect was discovered in L. delbrueckii subsp. bulgaricus. It shows improved survivability against freeze-drying when more lactobacillic acid is present in the cell membrane.
== Education == Lebanon Community School Corporation has six schools under its jurisdiction: four elementary schools, a middle school and a high school. The body enrolled 3,381 students for the 2019–2020 school year, and it is recognized as a "B" district by the Indiana Department of Education. The six schools are:
Cartilage is a connective skeletal tissue composed of specialized cells called chondrocytes that in an extracellular matrix. This matrix is typically composed of Type II collagen fibers, proteoglycans, and water. There are many types of cartilage, including elastic cartilage, hyaline cartilage, fibrocartilage, and lipohyaline cartilage. Unlike other connective tissues, cartilage does not contain blood vessels. The chondrocytes are supplied by diffusion, helped by the pumping action generated by compression of the articular cartilage or flexion of the elastic cartilage. Thus, compared to other connective tissues, cartilage grows and repairs more slowly.
Sources: en.wikipedia.org
== Pathophysiology == Articular cartilage is composed of 60-80% water and components of collagens. Its functions are to maintain structure with a lifetime of stress and repetition of movement. Biological repair and cellular turnover is therefore limited leading to the restricted response to traumatic injury. Destruction of the cartilage leads to an activation of an inflammatory cascade leading to regeneration or destruction of the cartilage, the basis of posttraumatic osteoarthritis. These fracture patterns are likely a result of shearing, rotatory, or tangential forces applied to the joint producing segments of both bone and cartilage. The fracture generally run parallel to the joint surface and may be displaced or non displaced. Fragments of this fracture undergo two pathways of healing depending on size and degree of displacement: resorption or loose body formation. If there is vascular communication of the fracture fragment, there is a chance the body will continue to supply that fragment and it will be remained attached to the bone. If there is a disruption of vasculature in the fragment, secondary ossification will occur and the fragment will become a loose body in the joint. With both pathways, there is a continued risk of posttraumatic arthritis and changes to load distribution to the joint.
Samir Mitragotri (born 28 May 1971) is an Indian American professor at Harvard University, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is currently the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. Prior to 2017, he was the Duncan and Suzanne Mellichamp Chair Professor at University of California, Santa Barbara.
As the head group forms such compact bicycle structure, the head group area is quite small relative to the big tail region consisting of 4 acyl chains. Based on this special structure, the fluorescent mitochondrial indicator, nonyl acridine orange (NAO) was introduced in 1982, and was later found to target mitochondria by binding to CL. NAO has a very large head and small tail structure which can compensate with cardiolipin's small head and large tail structure, and arrange in a highly ordered way. Several studies were published utilizing NAO both as a quantitative mitochondrial indicator and an indicator of CL content in mitochondria. However, NAO is influenced by membrane potential and/or the spatial arrangement of CL, so it's not proper to use NAO for CL or mitochondria quantitative studies of intact respiring mitochondria. But NAO still represents a simple method of assessing CL content.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.